Consensus Framework for the Optimal Delivery of Bispecific Antibodies in Multiple Myeloma
The EMMBRAce Project (Equity in Multiple Myeloma Bispecific Research and Access) is dedicated to ensuring that patients with myeloma across the UK have fair and equitable access to the latest treatments, including the NICE-approved teclistamab and eranatamab. As these therapies become more widely available, the team’s focus is on overcoming the challenges associated with their delivery, particularly in non-transplant centres.
A multidisciplinary team of NHS haematology professionals is working to support hospitals in developing the necessary infrastructure to provide bispecific antibodies to myeloma patients. Their goal is to ensure that all eligible patients, including those from underserved groups, can benefit from these life-changing treatments.
Resources available
The EMMBRAce Project website provides a range of resources designed to help healthcare providers implement bispecific antibody therapies. These include:
- Guidance on service development
- Referral templates
- Educational resources
Who will benefit
The initial beneficiaries of this project will be patients who have undergone multiple lines of treatment and are triple-class exposed (PI, IMiD, and CD38 Mab). As bispecific treatments move to earlier lines and combination therapies, the project will expand to include a wider range of indications, improving access to clinical trials and reducing inequalities in treatment access.
In particular, the project aims to address disparities in treatment access among underserved groups, such as patients from black and Asian communities or those from low socio-economic backgrounds. These patients often face challenges in accessing timely treatments, and the project will work to reduce these barriers by enabling more local hospitals to provide bispecific antibody therapies.
Learn more
For more information about the EMMBRAce Project and to access valuable resources for your hospital, please contact the team at Uclh.emmbrace.queries@nhs.net